



**A TORRENT  
GROUP COMPANY**

**Sub: J. B. Chemicals & Pharmaceuticals Ltd. – Final Dividend of FY 2025-26 Communication on Tax Deduction at source (TDS)/ withholding tax on Dividend**

**This communication is important and requires your immediate attention.**

Dear Shareholder,

We hope that this letter finds you in good health.

We are pleased to inform you that the Board of Directors of the Company, at its meeting held on May 11, 2026 has recommended final dividend of ` 9.30/- per equity share of ` 1/- each for the financial year 2025-2026, which shall be remitted on or after June 22, 2026, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting.

As you may be aware, pursuant to changes introduced by the Finance Act 2020, with effect from April 1, 2020, dividend income will be taxable in the hands of shareholders and the Company would be liable to withhold tax at the prescribed rates on the dividend paid to its shareholders. The withholding tax rate would vary depending on the residential status of the shareholder and the documents submitted and accepted by the Company. Accordingly, the final dividend will be paid after deducting tax at source as under:

**For Resident Shareholders:**

Particulars	Applicable Rate	Documents required (if any)
With PAN	10% <sup>1</sup>	Update PAN with the Company / Registrar and Transfer Agents (in case of shares held in physical mode) and Depository (in case of shares held in demat mode).

<sup>1</sup> No TDS would be applied to resident individual shareholder, if total dividend paid in FY 2026-27 does not exceed INR 10,000.



**A TORRENT  
GROUP COMPANY**

		<b>No deduction of taxes in the following case –</b>  If the shareholder is exempted from TDS provisions through any circular or notification and provides an attested copy of the PAN along with the documentary evidence in relation to the same.
Other resident shareholders without registration of PAN or having Invalid, Inoperative <sup>2</sup> or Incorrect PAN u/s 397(2) of the Income Tax Act, 2025 <sup>3</sup>	20% <sup>1</sup>	-
Submitting Form 121 (earlier Form 15G/ Form 15H)	NIL	Duly filled and signed declaration in Form No. 121, along with self-attested copy of their PAN, in case, shareholder is eligible for the same.  Blank Form 121 can be downloaded from the Company's website <a href="http://www.jbpharma.com">www.jbpharma.com</a>  Please note that all the fields of Form 121 are required to be filled mandatorily. Incomplete forms would be liable to be rejected by the Company.

<sup>2</sup> The last date for linking Aadhar with PAN was June 30, 2023. The PAN of a person has become inoperative from July 1, 2023 in case the same was not linked to his / her Aadhaar card as per section 262 of the Income Tax Act, 2025.

<sup>3</sup> Section 397(2) mandates a higher TDS rate if the recipient/shareholder fails to provide his/her PAN, or having an invalid, inoperative or incorrect PAN with rate being the highest of the applicable rates, or at flat 20%.

**Registered Office:**  
**J. B. Chemicals & Pharmaceuticals Limited**  
CIN: L24390GJ1976PLC173077  
302, Iscon Mall, Star India Bazar Building,  
Opp. Jodhpur BRTS Satellite,  
Ahmedabad- 380015, Gujarat, India  
Email: [secretarial@jbpharma.com](mailto:secretarial@jbpharma.com)

**Corporate Office:**  
**J. B. Chemicals & Pharmaceuticals Limited**  
CIN: L24390GJ1976PLC173077  
Energy IT Park, Unit A, 3<sup>rd</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai 400 025.  
Tel.:+91 22 2439 5200/5500

[www.jbpharma.com](http://www.jbpharma.com)



**A TORRENT<sup>®</sup>  
GROUP COMPANY**

Mutual Funds	NIL	Documentary evidence to prove that the mutual fund is specified under Schedule VII (Table: Sl. No 20 or 21) of the Income Tax Act, 2025 along-with self-attested copy of the registration certificate and PAN.
Insurance companies	NIL	Documentary evidence to prove that the insurance company is specified under section 2(7A) of the Insurance Act, 1938 along-with self-attested copy of the registration certificate and PAN.
Domestic Alternative Investment Fund (AIF)	NIL	Documentary evidence to prove that the AIF is a fund eligible for exemption under Schedule V (Table: Sl. No 1) of the Income Tax Act, 2025 and is registered as Category I or Category II AIF under SEBI regulations, along-with self-attested copy of registration certificate and PAN.
Submitting Order u/s 395 of the Income Tax Act, 2025	Rate provided in order	Lower/NIL withholding tax certificate obtained from tax authority.
Recognized Provident fund/ Approved Superannuation fund/ Approved Gratuity Fund	NIL	Documentary evidence that the person is covered by Circular No. 18/2017 dated May 29, 2017.
New Pension System Trust	NIL	Documentary evidence that the person is covered under Schedule VII (Table: Sl. No. 41). of the Income Tax Act, 2025.
Shareholder to whom Section 393(1) of the Income Tax Act, 2025 is not applicable	NIL	Documentary evidence that the said provisions are not applicable.
Person Covered u/s 393(1) of the Income Tax Act, 2025	NIL	Documentary evidence that person is covered under section 393(1) of the Income Tax Act, 2025.

**Registered Office:**

**J. B. Chemicals & Pharmaceuticals Limited**  
**CIN:** L24390GJ1976PLC173077  
302, Iscon Mall, Star India Bazar Building,  
Opp. Jodhpur BRTS Satellite,  
Ahmedabad- 380015, Gujarat, India  
Email: [secretarial@jbpharma.com](mailto:secretarial@jbpharma.com)

**Corporate Office:**

**J. B. Chemicals & Pharmaceuticals Limited**  
**CIN:** L24390GJ1976PLC173077  
Energy IT Park, Unit A, 3<sup>rd</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai 400 025.  
Tel.:+91 22 2439 5200/5500



**A TORRENT<sup>™</sup>  
GROUP COMPANY**

**For Non-Resident Shareholders:**

<b>Particulars</b>	<b>Applicable Rate</b>	<b>Documents required (if any)</b>
Non-resident shareholders (including FII/FPI)	20% (plus applicable surcharge and cess) or Tax Treaty Rate <sup>4</sup> <b>(Whichever is lower)</b>	In order to apply the beneficial Tax Treaty rate, following documents would be required: 1) Copy of Indian Tax Identification number (PAN), if available 2) Tax Residency Certificate (TRC) obtained from the tax authorities of the country of which the shareholder is resident 3) Duly filled and signed Form 41 as required under the provisions of Income-Tax Act. <sup>5</sup> 4) Self-Declaration from Non-resident shareholder, covering following: - Non-resident shareholder is and will continue to remain a tax resident of the country of its residence during the Financial Year 2026-27. - Non-resident shareholder is eligible to claim the benefit of respective tax treaty

<sup>4</sup> The Company is not obligated to apply the beneficial Tax Treaty rates at the time of tax deduction/withholding on dividend amounts. Application of beneficial Tax Treaty Rate shall depend upon the completeness and satisfactory review by the Company, of the documents submitted by Non-Resident shareholder.

<sup>5</sup> Furnishing Form 41 on the Indian Income Tax Portal is mandated by Notification No. 03/2022, dated 16-07-2022. Shareholders shall need to login into the Income Tax Portal and file Form 41 online and share the final copy with the Company.



**A TORRENT  
GROUP COMPANY**

		<ul style="list-style-type: none"><li>- Non-resident shareholder receiving the dividend income is beneficial owner of such income</li><li>- Dividend income is not attributable /effectively connected to any Permanent Establishment (PE) or Fixed Base in India.</li></ul>
Submitting Order u/s 395 of the Income Tax Act, 2025	Rate provided in order	Lower/NIL withholding tax certificate obtained from tax authority.

**TDS rate in case of taxpayers u/s 397(2) who fails to provide their PAN, or having an Invalid, Inoperative or Incorrect PAN:**

In cases where Section 397(2) is applicable i.e. the shareholder has not submitted PAN or having an Invalid, Inoperative or Incorrect PAN, tax will be deducted at higher of the rates prescribed in the said section.

**Multiple accounts under different status/category:**

Shareholders holding shares under multiple accounts under different status / category and single PAN, may note that higher of the tax rates as applicable to the status in which the shares are held under a single PAN will be considered on the entire holding under multiple accounts.

**Joint holding:**

In case of joint shareholders, the shareholder named first in the Register of Members is required to furnish the requisite documents for claiming any applicable beneficial tax rate.

**Updation of PAN, Contact information and Bank Account details:**

Shareholders holding shares in physical form are requested to note that SEBI, vide its circular dated November 03, 2021 (subsequently amended by circulars dated December 14, 2021, March 16, 2023 and November 17, 2023) mandated that the security holders, holding securities in physical form, whose folio(s) do not have PAN, Choice of Nomination, Contact



**A TORRENT  
GROUP COMPANY**

Details, Mobile Number, Bank Account Details, Specimen Signature updated, shall be eligible for any payment including dividend, interest or redemption in respect of such folios, only through electronic mode with effect from April 01, 2024, upon their furnishing all the aforesaid details in entirety to Registrar and Transfer Agent.

Shareholders holding shares in dematerialised mode are requested to update the above details through their depository participants.

**Declaration under Rule 203**

In terms of Rule 203 of the Income Tax Rules, 2026, if dividend income on which tax has been deducted at source is assessable in the hands of a person other than the deductee, then such deductee should file declaration with Company in the manner prescribed in the Rules. **Such declarations should be submitted to the Company before the payment of dividend by the Company.** The draft format is available on the Company's website [www.jbpharma.com](http://www.jbpharma.com).

The aforesaid documents, as applicable, may be sent to the Company at its office address at 'The Company Secretary, J. B. Chemicals & Pharmaceuticals Limited, Neelam Centre, B Wing, 4<sup>th</sup> floor, Hind Cycle Road, Worli, Mumbai – 400 030' or emailed at [investorelations@jbpharma.com](mailto:investorelations@jbpharma.com) **on or before May 31, 2026** to enable us to determine the appropriate TDS / withholding tax rate applicable. If any details/documents for tax determination/deduction are received post May 31, 2026, it shall not be considered for payment of final dividend.

In the event, the tax on said final dividend is deducted at a higher rate in absence of receipt of the aforementioned details/documents from shareholders by May 31, 2026, you may claim appropriate refund in the return of income to be filed by you with the Income Tax authorities.

**No claim shall lie against the Company for such taxes deducted.**

We shall arrange to send a soft copy of TDS certificate to you on your registered email ID in due course, post payment of the said final dividend. You would be able to see the credit of TDS in Form 26AS, which you can download from e-filing account at [www.incometax.gov.in](http://www.incometax.gov.in).

Yours faithfully,

**For J. B. Chemicals & Pharmaceuticals Ltd.**

**Sandeep Phadnis  
Company Secretary**